| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Total operating expenses | 95,285 | 96,033 | 75,865 | |
| Loss from operations | -92,521 | -84,557 | -72,124 | |
| Interest and other income | 10,444 | 8,051 | 9,697 | |
| Interest and other expense | 98 | 108 | 60 | |
| Total other income | 10,346 | 7,943 | 9,637 | |
| Net loss | -82,175 | -76,614 | -62,487 | |
| Unrealized gain on marketable securities | 1,222 | 337 | 4,030 | |
| Total comprehensive loss | -80,953 | -76,277 | -58,457 | |
| Net loss per share, basic | -0.94 | -0.95 | -0.82 | |
| Net loss per share, diluted | -0.94 | -0.95 | -0.82 | |
| Weighted average common shares outstanding, basic | 87,300,286 | 80,449,405 | 76,125,975 | |
| Weighted average common shares outstanding, diluted | 87,300,286 | 80,449,405 | 76,125,975 | |
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)